^
Association details:
| Biomarker: | ER-L |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Biomarkers of resistance to palbociclib in ER+ primary breast cancer in the PALLET trial
Published date:
11/17/2020
Excerpt:
307 patients were randomized to LET (n=103) or LET+PALBO (n=204) for 14 wks...Lower levels of ER, higher levels of cyclin-E1, and amplification of cyclin-D1 were each significantly associated with a greater chance of non-CCCA with LET+PALBO….These results suggest that multiple identifiable mechanisms of de novo resistance to PALBO are likely to exist in primary ER+ BC.
Secondary therapy:
letrozole
Trial ID:
